- AstraZeneca India’s net income for the fourth quarter is 394.8 million rupees, a significant increase from 172.7 million rupees year-over-year.
- Revenue for the quarter reached 3.83 billion rupees, marking a 34% increase compared to the same period last year.
- Total costs for the quarter rose by 47% year-over-year, amounting to 3.38 billion rupees.
- The company declared a dividend of 24 rupees per share.
- AstraZeneca India shares rose by 6.8%, closing at 6,433 rupees, with a trading volume of 164,969 shares.
- No buy, hold, or sell recommendations were reported for the shares.
- All comparisons are based on values reported from the company’s original disclosures.
“`
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using Smartkarma Smart Scores indicate a positive long-term outlook for AstraZeneca PLC, a company that operates within the pharmaceutical industry. With a strong emphasis on growth and momentum, AstraZeneca scores well in these areas. This suggests that the company is positioned for future expansion and has positive market momentum.
AstraZeneca also demonstrates average scores in terms of value, dividend, and resilience. While these scores are not as high as growth and momentum, they still show stability within the company. Overall, AstraZeneca is recognized for its focus on research, manufacturing, and sales of pharmaceutical and medical products across various therapeutic areas.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
